Acute phase reactant, Pentraxin 3, as a novel marker for the diagnosis of rheumatoid arthritis

PTX3 found to be sensitive non-invasive indicator of clinical arthritic activity in RA patients when compared to traditional markers like CRP. Combination of PTX3 and CRP could serve as better differential diagnostic markers for RA after validation in larger patient cohort.